BEAM THERAPEUTICS INC(NASDAQ:BEAM) stock News

BEAM Latest News, Press Relases and Analysis

All

Press Releases

5 hours ago - By: Zacks Investment Research - Mentions: CRSP

Will Beam Therapeutics Inc. (BEAM) Report Negative Q2 Earnings? What You Should Know

23 days ago - By: Yahoo Finance

H.C. Wainwright Reiterates a Buy Rating on Beam Therapeutics (BEAM) With an $80 PT

a month ago - By: Yahoo Finance - Mentions: CERT INSP

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

a month ago - By: The Motley Fool - Mentions: TMDX PODD OPCH LFMD ...

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

3 months ago - By: Benzinga

10 Analysts Assess Beam Therapeutics: What You Need To Know

a month ago - By: Benzinga - Mentions: COIN ESLT KTOS TSLA ...

Cathie Wood's Ark Invest Continues To Offload Coinbase, Bets Big On SoFi Technologies

a month ago - By: Investor's Business Daily - Mentions: GILD CRSP SRPT LEGN ...

The FDA Shake-Up Continues, And Could Impact Genetic Medicines

a month ago - By: Investor's Business Daily - Mentions: LLY VERV NTLA EDIT ...

Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover

a month ago - By: Yahoo Finance - Mentions: LLY VERV KHC NTLA

Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B

2 months ago - By: Beam Therapeutics

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

2 months ago - By: Beam Therapeutics

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

2 months ago - By: Zacks Investment Research - Mentions: BMY

Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue?

2 months ago - By: Yahoo Finance - Mentions: DLTR NTLA SMCI NVDA

Biotech funding plummets as Trump policies unnerve investors: Jefferies

2 months ago - By: Beam Therapeutics

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

2 months ago - By: Yahoo Finance - Mentions: REVB ESLT CTKB KROS ...

Revelation Biosciences, Inc. (REVB) Raises $4M in Public Offering

2 months ago - By: Yahoo Finance - Mentions: VREX CTKB KROS CADL ...

Varex Imaging Corporation (VREX) Downgraded by S&P as Regulatory Outlook Remains Cloudy

2 months ago - By: Beam Therapeutics

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

2 months ago - By: Beam Therapeutics

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

2 months ago - By: Zacks Investment Research - Mentions: ILMN QURE NTLA CRSP ...

3 Top Genomics Stocks to Add to Your Portfolio in 2025

3 months ago - By: Beam Therapeutics

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

3 months ago - By: Beam Therapeutics

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

3 months ago - By: Beam Therapeutics

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference

3 months ago - By: Beam Therapeutics

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

3 months ago - By: Beam Therapeutics

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

3 months ago - By: Zacks Investment Research - Mentions: SNY ADMA KYMR

Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging

3 months ago - By: Zacks Investment Research - Mentions: INSM ADPT ELEV

Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates

3 months ago - By: Zacks Investment Research - Mentions: REGN ANIP NTLA

Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up

3 months ago - By: Zacks Investment Research - Mentions: PCRX ADMA

Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates

3 months ago - By: Zacks Investment Research - Mentions: ADMA RCKT

RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus

3 months ago - By: Zacks Investment Research - Mentions: SNY NVAX ADPT

NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up

3 months ago - By: Zacks Investment Research - Mentions: ADPT IOVA ELEV

Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut

3 months ago - By: Zacks Investment Research - Mentions: ADMA VTRS

Viatris Q1 Earnings and Revenues Beat Estimates, Stock Gains

3 months ago - By: Zacks Investment Research - Mentions: ANIP NTLA MIRM

Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised

3 months ago - By: Zacks Investment Research - Mentions: AMRN ANIP NTLA

Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y

3 months ago - By: Zacks Investment Research - Mentions: CPRX ADMA

Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y

3 months ago - By: Zacks Investment Research - Mentions: ADMA APLS

Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down

3 months ago - By: Zacks Investment Research - Mentions: ADMA ACAD

Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth

3 months ago - By: Zacks Investment Research - Mentions: ANIP NTLA IMCR

BEAM THERAPEUTICS INC (BEAM) Stock News

BEAM Latest News, Press Relases and Analysis

Will Beam Therapeutics Inc. (BEAM) Report Negative Q2 Earnings? What You Should Know

H.C. Wainwright Reiterates a Buy Rating on Beam Therapeutics (BEAM) With an $80 PT

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

10 Analysts Assess Beam Therapeutics: What You Need To Know

Cathie Wood's Ark Invest Continues To Offload Coinbase, Bets Big On SoFi Technologies

The FDA Shake-Up Continues, And Could Impact Genetic Medicines

Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover

Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue?

Biotech funding plummets as Trump policies unnerve investors: Jefferies

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

Revelation Biosciences, Inc. (REVB) Raises $4M in Public Offering

Varex Imaging Corporation (VREX) Downgraded by S&P as Regulatory Outlook Remains Cloudy

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

3 Top Genomics Stocks to Add to Your Portfolio in 2025

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging

Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates

Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up

Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates

RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus

NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up

Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut

Viatris Q1 Earnings and Revenues Beat Estimates, Stock Gains

Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised

Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y

Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y

Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down

Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth

BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates